Literature DB >> 25408230

Lessons learned from the clinical development of oral peptides.

Morten Asser Karsdal1, Bente Juul Riis, Nozer Mehta, William Stern, Ehud Arbit, Claus Christiansen, Kim Henriksen.   

Abstract

The oral delivery of peptides and proteins has been hampered by an array of obstacles. However, several promising novel oral delivery systems have been developed. This paper reviews the most advanced oral formulation technologies, and highlights key lessons and implications from studies undertaken to date with these oral formulations. Special interest is given to oral salmon calcitonin (CT), glucagon-like peptide-1 (GLP-1), insulin, PYY-(3-36), recombinant human parathyroid hormone (rhPTH(1-31)-NH2) and PTH(1-34), by different technologies. The issues addressed include (i) interaction with water, (ii) interaction with food, (iii) diurnal variation, (iv) inter- and intra-subject variability, (v) correlation between efficacy and exposure and (vi) key deliverables of different technologies. These key lessons may aid research in the development of other oral formulations.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  bone; calcitonin; cartilage; clinical trial; diabetes; oral formulation

Mesh:

Substances:

Year:  2015        PMID: 25408230      PMCID: PMC4415709          DOI: 10.1111/bcp.12557

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  92 in total

1.  Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers.

Authors:  C J Watson; M Rowland; G Warhurst
Journal:  Am J Physiol Cell Physiol       Date:  2001-08       Impact factor: 4.249

Review 2.  The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins.

Authors:  A Bernkop-Schnürch
Journal:  J Control Release       Date:  1998-03-02       Impact factor: 9.776

3.  A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects.

Authors:  A Khedkar; H Iyer; A Anand; M Verma; S Krishnamurthy; S Savale; A Atignal
Journal:  Diabetes Obes Metab       Date:  2010-08       Impact factor: 6.577

4.  Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.

Authors:  Yu Z Bagger; László B Tankó; Peter Alexandersen; Morten A Karsdal; Melvin Olson; Linda Mindeholm; Moïse Azria; Claus Christiansen
Journal:  Bone       Date:  2005-09       Impact factor: 4.398

5.  Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis.

Authors:  Daniel-Henri Manicourt; Moïse Azria; Linda Mindeholm; Eugene J-M Thonar; Jean-Pierre Devogelaer
Journal:  Arthritis Rheum       Date:  2006-10

Review 6.  Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality.

Authors:  Morten A Karsdal; Kim Henriksen; Michel Arnold; Claus Christiansen
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

7.  The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model.

Authors:  Bodil-Cecilie Sondergaard; Svetlana Oestergaard; Claus Christiansen; Laszló B Tankó; Morten Asser Karsdal
Journal:  Arthritis Rheum       Date:  2007-08

8.  Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles.

Authors:  Kishore B Chalasani; Gregory J Russell-Jones; Akhlesh K Jain; Prakash V Diwan; Sanjay K Jain
Journal:  J Control Release       Date:  2007-05-24       Impact factor: 9.776

9.  Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study.

Authors:  Roy Eldor; Ehud Arbit; Asher Corcos; Miriam Kidron
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

10.  The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality.

Authors:  M A Karsdal; I Byrjalsen; D J Leeming; P D Delmas; C Christiansen
Journal:  Osteoporos Int       Date:  2008-04-03       Impact factor: 5.071

View more
  6 in total

Review 1.  Safety concerns over the use of intestinal permeation enhancers: A mini-review.

Authors:  Fiona McCartney; John P Gleeson; David J Brayden
Journal:  Tissue Barriers       Date:  2016-04-12

Review 2.  Peptide regulation of cofilin activity in the CNS: A novel therapeutic approach for treatment of multiple neurological disorders.

Authors:  Alisa E Shaw; James R Bamburg
Journal:  Pharmacol Ther       Date:  2017-02-20       Impact factor: 12.310

3.  Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.

Authors:  Andreas B Jordy; Muna Albayaty; Astrid Breitschaft; Thomas W Anderson; Erik Christiansen; Azadeh Houshmand-Øregaard; Easwaran Manigandan; Tine A Bækdal
Journal:  Clin Pharmacokinet       Date:  2021-09       Impact factor: 5.577

4.  Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.

Authors:  Ross W Cheloha; Bingming Chen; Niyanta N Kumar; Tomoyuki Watanabe; Robert G Thorne; Lingjun Li; Thomas J Gardella; Samuel H Gellman
Journal:  J Med Chem       Date:  2017-10-24       Impact factor: 7.446

Review 5.  Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.

Authors:  Renata Kowalczyk; Paul W R Harris; Geoffrey M Williams; Sung-Hyun Yang; Margaret A Brimble
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

6.  Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.

Authors:  Wenbo Sai; Hong Tian; Kangmin Yang; Daoqi Tang; Jinxiao Bao; Yang Ge; Xiaoda Song; Yu Zhang; Cheng Luo; Xiangdong Gao; Wenbing Yao
Journal:  Int J Mol Sci       Date:  2017-03-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.